PI3K/Akt通路在δ-阿片受体介导的视网膜神经节细胞神经保护中的作用
本研究在慢性青光眼大鼠模型中探讨PI3K/Akt通路在δ-阿片受体激动剂SNC-121诱导的视网膜神经节细胞(RGC)神经保护中的作用。高渗盐水注入Brown Norway大鼠角膜缘静脉升高眼压,每日给予1 mg/kg SNC-121或3 mg/kg PI3K/Akt抑制剂LY-294002加SNC-121,持续7天。SNC-121激活ONH星形胶质细胞和视网膜中的PI3K/Akt通路,逆转高眼压视网膜和视神经中Akt活化的持续下降,显著增加图形ERG波幅和RGC数量,而LY-294002预处理抑制了这些增加;SNC-121还抑制视神经和TNF-α处理的ONH星形胶质细胞中MMP-1、-2、-3的产生。结论认为PI3K/Akt通路在SNC-121介导的RGC对抗青光眼损伤的神经保护中起关键作用。
要点
- SNC-121激活ONH星形胶质细胞和视网膜中的PI3K/Akt通路,PI3K/Akt抑制剂可完全抑制SNC-121诱导的Akt活化。
- 高眼压视网膜和视神经中Akt活化在损伤后7-42天持续下降,1 mg/kg腹腔注射SNC-121可使其恢复至正常水平。
- SNC-121增加高眼压眼图形ERG波幅和RGC数量,LY-294002预处理可抑制该增加;SNC-121抑制视神经和TNF-α处理的ONH星形胶质细胞中MMP-1、-2、-3产生。
核心结论
- PI3K/Akt通路在SNC-121介导的RGC对抗青光眼损伤的神经保护中起关键作用。
研究设计与样本
- 研究采用慢性青光眼大鼠模型,向Brown Norway大鼠角膜缘静脉注射高渗盐水升高眼压。
- 大鼠每日接受1 mg/kg SNC-121或3 mg/kg LY-294002加SNC-121治疗,持续7天。
- 采用图形ERG记录、Fluorogold逆行标记RGC、免疫组化和Western blotting检测。
- ONH星形胶质细胞先用PI3K/Akt抑制剂预处理30分钟,再用1-μM SNC-121处理。
主要发现
- SNC-121激活ONH星形胶质细胞和视网膜中的PI3K/Akt通路,SNC-121诱导的Akt活化在ONH星形胶质细胞中被PI3K/Akt抑制剂完全抑制。
- 高眼压视网膜和视神经中Akt活化在损伤后7-42天持续下降,1 mg/kg腹腔注射SNC-121治疗可使其恢复至正常水平。
- 高眼压眼图形ERG波幅和RGC数量均降低,SNC-121治疗的动物中两者显著增加。
- SNC-121诱导的图形ERG波幅和RGC数量增加在LY-294002预处理的动物中被抑制。
- SNC-121治疗抑制高眼压大鼠视神经和TNF-α处理的ONH星形胶质细胞中MMP-1、-2、-3的产生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study examines the role of PI3K/Akt pathway in δ-opioid receptor agonist (SNC-121)-induced RGC neuroprotection in a chronic glaucoma rat model. METHODS: Injecting hypertonic saline into the limbal veins of Brown Norway rats elevated IOP. Rats were treated either with 1 mg/kg SNC-121 or 3 mg/kg 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride (LY-294002; PI3K/Akt inhibitor) plus SNC-121 once daily for 7 days. Pattern ERGs were recorded in response to contrast reversal of patterned visual stimuli. Retinal ganglion cells (RGC) were visualized by Fluorogold retrograde labeling. Optic nerve head (ONH) astrocytes were pretreated with PI3K/Akt inhibitors for 30 minutes followed by 1-μM SNC-121 treatment. Changes in matrix metalloproteinases (MMP-1, -2, and -3) production and PI3K/Akt activation in optic nerve and TNF-α treated ONH astrocytes were measured by immunohistochemistry and Western blotting. RESULTS: SNC-121 activates the PI3K/Akt pathway in ONH astrocytes and the retina. In ONH astrocytes, SNC-121-induced Akt activation was fully inhibited by PI3K/Akt inhibitors. A sustained decline (7-42 days post injury) in Akt activation was seen in the ocular-hypertensive retina and optic nerve. This decline is reversed to normal levels by 1-mg/kg intraperitoneally (i.p.) SNC-121 treatment. Both pattern ERG amplitudes and RGC numbers were reduced in ocular hypertensive eyes, which were significantly increased in SNC-121-treated animals. Interestingly, SNC-121-induced increase in pattern-ERG amplitudes and RGC numbers were inhibited in LY-294002 pretreated animals. Additionally, SNC-121 treatment inhibited MMP-1, -2, and -3 production from the optic nerve of ocular hypertensive rats and TNF-α-treated ONH astrocytes. CONCLUSIONS: PI3K/Akt pathway plays a crucial role in SNC-121-mediated RGC neuroprotection against glaucomatous injury.
引用
- Husain S, Ahmad A, Singh S, et al. PI3K/Akt Pathway: A Role in δ-Opioid Receptor-Mediated RGC Neuroprotection. Invest Ophthalmol Vis Sci. 2017. PMID: 29288267. doi:10.1167/iovs.16-20673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。